Ryght AI and Cancer Research SA (CRSA) Partner to Enhance Cancer Clinical Trials in South Australia
CRSA Joins Ryght Research Network to Accelerate Access to Novel Cancer Therapies LAGUNA BEACH, Calif., Jan. 28, 2025 /PRNewswire/ -- Ryght...
Cancer
2024 ISS National Lab Annual Report Highlights Momentum in Space-Based R&D
ISS National Lab Delivers More Than 100 Payloads to Laboratory in Low Earth Orbit and Expands Resources to Dozens of...
Cordance Medical and EXACT Therapeutics Announce Early Encouraging Data in Brain Cancer Mice Model
MOUNTAIN VIEW, Calif. and OSLO, Norway, Jan. 28, 2025 /PRNewswire/ -- Cordance Medical, a pioneer in non-invasive medical technologies for...
Cooper University Health Care Breaks Ground on First Phase of $3 Billion “Project Imagine” Expansion in Camden
Camden, New Jersey--(Newsfile Corp. - January 28, 2025) - Today, Cooper University Health Care held a groundbreaking ceremony on the...
Definitive JSCDM Article Shows the Power and Value of nCartes EHR-to-EDC
FREMONT, Calif., Jan. 28, 2025 /PRNewswire/ -- Automating data capture by leveraging electronic health records can significantly improve data quality...
SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities
The cutting-edge OncoPortal™ Mutation Tracker add-on module enables precision monitoring of evolving genomic cancer drivers BOSTON, MA and ROLLE, Switzerland,...
Okomera to Present Automated Desktop Organoid Screening Instrument for Oncology Drug Discovery at SLAS 2025 in San Diego
PARIS, Jan. 28, 2025 /PRNewswire/ -- Okomera is a biotech startup developing cutting-edge solutions for oncology drug discovery and will...
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader
Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY™, a registrational-stage diagnostic asset,...
Persephone Biosciences Announces Full Enrollment in AMBROSIA Food as Medicine Study
- 400 participants with a medium-to-high risk of developing colorectal cancer (CRC) have been enrolled across two arms - -...
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Dual-Targeted CD19/CD70 Allogeneic CAR T: Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune...
Eterna Therapeutics Announces Expansion of Scientific Advisory Board
Dr. Jerome Zeldis and Dr. Blythe Sather bring exceptional backgrounds in cell therapy and solid tumorsCAMBRIDGE, Mass., Jan. 28, 2025...
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a...
Polarean and SimonMed Announce Collaboration to Advance Lung Imaging Innovation
One of the largest US outpatient medical imaging providers to introduce Xenon MRI platform to its network Polarean and SimonMed...
Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement
Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to...
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
Company prepares to advance to Phase 2 clinical trial in early 2025 HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March...
Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement
SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing...
Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference
NORWOOD, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced...
Anivive Secures $20 Million Investment from Leonid Capital Partners to Develop the Next Generation of Pet Health
Funding expands manufacturing readiness for Valley fever vaccineThis follows Anivive's $33MM NIAID contract for fungal vaccinesIn total, Anivive has secured...
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
- High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the...
Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT
Study is the first randomized, controlled trial examining a vaccine’s effectiveness in controlling CMV in recipients of HSCT from vaccinated...